Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-03-23

FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) from Novartis Pharmaceuticals Corporation, resulting in a labeling update. The snippet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRILEPTAL (OXCARBAZEPINE)

Snippet

SUPPL AP for TRILEPTAL (OXCARBAZEPINE)